Building on Last Year’s Advances
The 2015 ASCO Annual Meeting delivered new practice-changing results in the area of prostate cancer.
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer
Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223 and review the available data regarding the cost of denosumab compared with that of zoledronic acid.
Targeted Therapy in Prostate Cancer: Is There Hope Beyond the Androgen Receptor?
We need to understand each patient’s cancer and its microenvironment well enough to develop targeted treatments that will kill the tumor the first time-for if we let it escape, 70 years of prostate cancer research teaches us that our job will only get harder.
Treatment of Castration-Resistant Prostate Cancer: Current Options and Novel Therapies
Two experts discuss newly available and upcoming treatment options, such as abiraterone and MDV3100, for patients with castration-resistant prostate cancer.
2 Commerce Drive Cranbury, NJ 08512